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Background: It is not known if dysglycemia and sleep-disordered breathing are linked 
in adolescents, as in adults.
Objective: To perform a pilot study evaluating measures of sleep-disordered breathing 
across the spectrum of glucose tolerance in obese adolescents. We hypothesized that 
dysglycemia would be associated with sleep-disordered breathing.
Participants/methods: This was a prospective, cross-sectional clinical pilot study that 
included 57 adolescents [body mass index (BMI) 38.9 ± 8.4 kg/m2] aged 12–18 years 
(14.5 ±  1.6) with normal glucose tolerance (NGT), or dysglycemia [impaired glucose 
tolerance (IGT) or type 2 diabetes (T2D)].
Measures: Anthropometrics, overnight polysomnogram, and oral glucose tolerance 
tests were performed. Participant characteristics and outcome measures were com-
pared by glucose tolerance status. Correlational analyses were conducted to assess the 
associations between variables of interest.
results: Participants with dysglycemia (n = 21) were not different from those with NGT 
(n = 36) for BMI, waist circumference, body fat, or sleep characteristics. Nocturnal oxy-
gen desaturation was associated with higher BMI (r = −0.334, p = 0.012). The apnea–
hypopnea index (AHI) was not associated with physical and metabolic parameters. 
Although participants with dysglycemia tended to have higher AHIs (median 3.2, 2.2, 
and 1.6 events/h for T2D, IGT, and NGT, respectively), there was not a linear relationship 
between measures of glycemia and AHI.
conclusion: Further study with a larger proportion of youth with prediabetes and T2D 
is necessary to determine whether evaluation for sleep-disordered breathing is uniformly 
warranted.
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2Hannon et al. Sleep and Glucose Tolerance in Adolescents
Frontiers in Endocrinology | www.frontiersin.org June 2018 | Volume 9 | Article 281
inTrODUcTiOn
Prediabetes and type 2 diabetes (T2D) are strongly associated 
with obstructive sleep apnea (OSA) in adults (1). In the Look 
AHEAD study, >80% of overweight adult participants with T2D 
were found to have OSA on screening polysomnogram (PSG) 
(2). In adults, OSA is linked with higher hemoglobin A1C values 
across the range of glucose tolerance (3), and treatment of OSA 
has been associated with improvement in blood glucose control 
(4, 5). In youth, it is unknown if prediabetes and/or T2D and OSA 
or sleep-disordered breathing are linked, as few similar studies 
have been performed (6). In this pilot study, we sought to evaluate 
if sleep-disordered breathing is prevalent in obese adolescents 
with dysglycemia, and whether sleep-disordered breathing is 
associated with blood glucose measures. This is important to 
study in adolescents because: (1) adolescents have physiologic 
insulin resistance which increases risk for dysglycemia and 
development of prediabetes and T2D (7); (2) adolescents with 
obesity and T2D have particularly poor health outcomes (8, 9); 
and (3) longer exposure to T2D and sleep-disordered breathing 
may further exacerbate these poor health outcomes.
The primary objective of this pilot study was (a) to evaluate 
PSG-derived measures of sleep-disordered breathing across the 
spectrum of glucose tolerance in obese adolescents. We utilized 
oral glucose tolerance tests (OGTT) to categorize youth as having 
normal glucose tolerance (NGT), or dysglycemia [OGTT values 
consistent with prediabetes defined as impaired fasting glucose 
(IFG) and/or impaired glucose tolerance (IGT), and T2D], and 
(b) to examine the associations between OGTT-derived measures 
of glucose tolerance, insulin sensitivity, and insulin secretion 
and PSG-derived measures of OSA. We hypothesized that obese 
youth with dysglycemia would have more characteristics of OSA 
than obese youth with NGT.
MaTerials anD MeThODs
This cross-sectional study was approved by the University of 
Pittsburgh and Indiana University Institutional Review Boards 
and performed in the Pediatric Clinical and Translational 
Research Center (Children’s Hospital of Pittsburgh) and the 
Indiana Clinical Research Center with collaboration from the 
clinical sleep centers at these institutions. Informed and written 
consent was obtained from a parent/guardian, and assent was 
obtained from participants. A convenience sample of eligible sub-
jects referred to outpatient weight management or endocrinology 
clinics for obesity, prediabetes, or T2D, and who also reported 
snoring were approached for participation. Eligibility criteria were 
12- to 18-year-old male or female adolescents (Tanner stage >1) 
of any race with body mass index (BMI) ≥95th percentile. 
Exclusion criteria included diagnosis of type 1 diabetes, current 
tonsillar hypertrophy, chronic disease, or medications that may 
interfere with sleep, endocrine function or glucose regulation, 
syndromic obesity, chronic upper or lower airway disease, smok-
ing, or current upper respiratory tract infection. Participants 
treated with either metformin and/or lifestyle recommendations 
were eligible, after discontinuing metformin/exercise treatment 
for 48 h before study. If there was a previous diagnosis of T2D, 
duration was less than 2  years for all participants. Ninety-six 
patients were screened for the study, and 57 participants enrolled 
and completed study visits after informed consent/assent was 
obtained. Data for part of this study cohort have been previously 
published (10–12).
study Procedures and assays
All participants had an examination by a pediatric endocrino-
logist that included assessment of pubertal development, anthro-
pometric measurements, and 53/57 had body composition by 
dual-energy X-ray absorptiometry (4 had body weights greater 
than machine limits). A fasting laboratory evaluation including 
HbA1C, glucose, and insulin, and 2-h OGTT (1.75 g/kg, maxi-
mum 75 g; glucose and insulin at −15, 0, +15, +30, +60, +90, and 
+120 min time points) was performed. Fifty-three of fifty-seven 
participants completed the OGTT without complications. The 
remaining participants had minor complications, usually related 
to loss of intravenous access, which prohibited frequent blood 
sampling or reduced sample volume. Plasma glucose was meas-
ured by the glucose oxidase method (Pittsburg) and the glucose 
hexokinase method (Indianapolis). Samples were re-measured in 
Indianapolis using the glucose hexokinase method when avail-
able. Plasma insulin was determined by Beckman Coulter DXI 
800 using a chemiluminescent sandwich assay (CV 6%).
Polysomnograms
Overnight PSGs were performed in the sleep lab either the night 
immediately preceding the OGTT or the night immediately fol-
lowing the OGTT. Due to scheduling issues, it was not possible to 
conduct all studies in the same order. There were no differences 
in outcomes based on timing of the OGTT. Data were recorded 
using either Sensormedics Somnostar Pro version 7.2 or the 
Sandman Elite 9.1 sleep diagnostic software, and applying the 
following EEG montage: F3M2, F4M1, C3M2, C4M1, O2M1, 
O1M2, L-EOG, R-EOG, chin EMG, limb EMG, and the follow-
ing cardiorespiratory parameters: SpO2 and pulse (Masimo), 
ETCO2 (Microstream NPB 70 and Capnograph Sleep by BCI), 
nasal pressure, airflow (nasal or oral thermistor), thoracic and 
abdominal excursion (uncalibrated respirator inductance ple-
thysmography), pulse, and ECG. The PSG data were interpreted 
by one of two sleep Board-certified co-investigators specific to the 
site where the PSG was performed, who had no knowledge of the 
participants’ metabolic status. Sleep architecture and respiratory 
disturbances including the minimum percent oxyhemoglobin 
saturation (SpO2) by pulse oximetry, arousal events per hour 
(sleep fragmentation), and the apnea–hypopnea index (AHI, 
total number of central and obstructive apnea and hypopnea 
events per 1  h of sleep), were hand-scored utilizing pediatric 
criteria and calculated following the AASM manual for scoring 
guidelines (13). Obstructive apneas were scored for a drop in 
the peak flow signal by ≥90% of the pre-event baseline using 
an oral thermal sensor lasting ≥90% for the duration of at least 
two breaths during baseline breathing and associated with the 
presence of respiratory efforts throughout the entire period of 
the absent flow. Hypopneas were scored for a drop by ≥30% of 
the pre-event baseline using nasal pressure lasting ≥two breaths 
duration in association with either ≥3% oxygen desaturation 
TaBle 1 | Characteristics of the study participants.
Total study population normoglycemic Dysglycemic p Value
Total (%) 57 (100) 36 (63.2) 21 (36.8)
Age, years (SD) 14.5 ± 1.6 14.5 ± 1.6 14.2 ± 1.7 0.50
Sex
Female 30 (52.6%) 15 (41.7%) 15 (71.4%) 0.03
Male 27 (47.4%) 21 (53.3%) 6 (28.6%)
Race
White 29 (50.9%) 19 (52.8%) 10 (47.6%) 0.66
Black 27 (47.4%) 16 (44.4%) 11 (52.4%)
Mixed race 1 (1.8%) 1 (2.8%) 0 (0%)
Body mass index (BMI) (kg/m2) 38.9 ± 8.4 (35.0, 28.4–61.6) 38.3 ± 8.4 (34.8, 28.4–61.6) 39.8 ± 8.5 (35.5, 28.7–57.1) 0.53
BMI SDS 3.88 ± 1.50 (3.43, 1.80–8.31) 3.83 ± 1.57 (3.35, 1.80–8.31) 3.95 ± 1.39 (3.80, 2.04–6.43) 0.77
Waist circumference (cm) 113.8 ± 17.8 (109.0, 78.1–155.0) 115.3 ± 16.6 (111.6, 91.4–155.0) 111.1 ± 19.8 (106.0, 78.1–149.0) 0.39
Body fat (%) 46.4 ± 6.1 (n = 53) (46.3, 36.7–58.5) 45.3 ± 5.7 (n = 32) (44.7, 36.8–58.5) 48.9 ± 6.1 (48.9, 36.7–57.2) 0.035
laboratory characteristics
HbA1c (%) 5.8 ± 1.3 (5.4, 4.5–12.0) 5.5 ± 0.8 (5.4, 4.5–9.6) 6.3 ± 1.8 (5.9, 5.0–12.0) 0.014
Fasting glucose (mg/dL) 98.3 ± 7.4 (91.5, 74–231) 88.6 ± 6.5 (89.3, 74–99) 114.9 ± 37.4 (101.0, 79–231) <0.001
OGTT 2-h glucose (mg/dL) 143 ± 52 (n = 56) (128, 89–332) 118.8 ± 13.7 (122, 89–138) 187.2 ± 66.5 (157.5, 98–332) <0.001
1/Fasting insulin (μU/mL) 0.0421 ± 0.0210 (n = 52)  
(0.0385, 0.0100–0.0900)
0.0481 ± 0.0210 (n = 34)  
(0.0446, 0.0200–0.0900)
0.0307 ± 0.0159 (n = 18)  
(0.0321, 0.0100–0.0700)
0.003
Insulinogenic index 3.79 ± 2.64 (n = 51)  
(3.01, 0.30–12.3)
3.60 ± 2.0 (n = 33)  
(3.27, 0.36–7.83)
4.14 ± 3.57 (n = 18)  
(2.63, 0.30–12.26)
0.95
Oral disposition index 13.6 ± 10.0 (n = 51) (11.8, 0.81–56.6) 15.4 ± 10.3 (n = 33) (13.9, 2.5–56.6) 10.2 ± 8.6 (n = 18) (7.0, 0.8–34.5) 0.022
sleep characteristics
Polysomnogram sleep time, min 411 ± 53 (415, 233–494) 406 ± 53 (415, 233–478) 419 ± 54 (414, 314–494) 0.61
Sleep latency, min 15.5 ± 14.4 (12.0, <1.0–67.0) 14.8 ± 13.6 (12.3, 1.0–67.0) 16.6 ± 16.0 (12.0, <1.0–54.0) 0.93
REM sleep, % of total 18.9 ± 5.2 18.9 ± 5.5 18.9 ± 4.6 0.99
Slow wave sleep, % of total 19.4 ± 7.1 20.0 ± 6.9 18.3 ± 7.6 0.42
Apnea–hypopnea Index (AHI), events/h 4.7 ± 8.1 (2.2, 0.0–50.4) 3.3 ± 4.1 (1.6, 0.0–20.0) 7.0 ± 11.0 (2.9, 0.0–50.4) 0.19
AHI <1 17 (29.8) 12 (33.3) 5 (23.8)
Mild obstructive sleep apnea (OSA); 
AHI ≥1 to <5
24 (42.1) 17 (47.2) 7 (33.3)
Moderate OSA; AHI ≥5 to <10 8 (14.0) 4 (11.1) 4 (19.0)
Severe OSA; AHI ≥10 8 (14.0) 3 (8.3) 5 (23.8)
Adult OSA cutoff met, AHI >5, n (%) 16 (28.1) 7 (19.4) 9 (42.9) 0.07a
Arousal index, events/h 9.7 ± 6.3 (8.4, 2.0–39.2) 9.4 ± 4.7 (8.7, 3.5–25.3) 10.3 ± 8.8 (7.9, 2.0–39.2) 0.67
Nadir SpO2, % 88.6 ± 6.5 (91, 58–96) 90.3 ± 4.7 (92, 77–96) 86.0 ± 8.4 (87.0, 58–94) 0.06
Data are means ± SD unless otherwise indicated. Median, range are given in parentheses for variables not normally distributed.
aFisher’s Exact Test for the proportion with AHI >5 in each group (normoglycemic and dysglycemic).
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from the pre-event baseline or the event is associated with an 
arousal. Nocturnal hypoxia is defined as the time spent with SpO2 
less than 90% for more than 5 min.
calculations
Insulin sensitivity was estimated using inverse fasting insulin (14). 
Insulin secretion was expressed as the ratio of the incremental 
response of insulin to glucose at 30 min during the OGTT [insu-
linogenic index (IGI), ΔI0–30/ΔG0–30], i.e., the IGI (15). Insulin 
secretion in relation to insulin sensitivity (oral disposition index) 
was calculated as (ΔI0–30/ΔG0–30 × 1/fasting insulin) (15). OGTT 
glucose and insulin areas under the curve (AUC) were calculated 
using the trapezoidal method.
statistical analysis
Demographic and clinical characteristics of the cohort were 
summarized, and participants were compared by glucose toler-
ance status [NGT or having dysglycemia (IFG, IGT, or T2D)]. 
Dysglycemia was defined as having IFG or IGT using American 
Diabetes Association (ADA) criteria (16). T2D was defined using 
ADA criteria for OGTT results (16). Data were log-transformed 
when not normally distributed. Scatter plots were used to examine 
the relationships between variables of interest for the entire study 
cohort, and for NGT and dysglycemia groups. Non-parametric 
tests for independent samples were performed using Kruskal–
Wallis one-way ANOVA. Spearman’s correlation coefficients were 
used to quantify linear correlations, as data were not uniformly 
distributed for the cohort. Given the pilot nature of the study, we 
did not perform a pre-study sample-size calculation to address 
whether or not OSA was related to prediabetes or T2D in adoles-
cent youth. Post hoc power analysis showed that with the current 
sample size, we had 80% power to detect correlation coefficients 
greater than 0.37 (17). Considering the preliminary nature of 
the investigation, we did not perform multiplicity adjustment. 
p Values < 0.05 were considered statistically significant. All analy-
ses were implemented using SPSS software (Version 24).
resUlTs
Characteristics of the participants are reported in Table  1. 
Thirty-six (63.2%) had OGTT results consistent with NGT; 21 
had dysglycemia on OGTT [IFG (n = 5), IGT (n = 11), both 
FigUre 1 | Association between 2-h oral glucose tolerance tests (OGTT) glucose concentration and nadir oxygen saturation during polysomnogram. (a) includes 
all data; (B) excludes one outlier.
TaBle 2 | Correlation coefficients for the associations of sleep measures with physical and metabolic parameters.
Body mass 
index
Waist circ. Body fat (%) hba1c Fasting glucose 2-h glucose 1/Fasting 
insulin
insulinogenic  
index
Oral  
disposition  
index
Arousal  
index,  
events/h
−0.074 (0.59) −0.031 (0.82) −0.164 (0.26) 0.151 (0.28) −0.086 (0.54) −0.074 (0.60) 0.044 (0.76) −0.064 (0.66) −0.094 (0.52)
Apnea– 
hypopnea  
index,  
events/h
0.175 (0.19) 0.169 (0.21) −0.037 (0.79) 0.044 (0.74) 0.184 (0.17) 0.156 (0.25) −0.089 (0.53) −0.087 (0.55) −0.177 (0.21)
Nadir  
SpO2, %
−0.318 (0.02) −0.263 (0.048) 0.081 (0.56) −0.087 (0.52) −0.266 (0.046) −0.284 (0.03) 0.239 (0.09) −0.056 (0.69) 0.068 (0.64)
Data are Spearman’s coefficients (p values).
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and sleep-disordered breathing (arousal events per hour, AHI, 
and nadir SpO2 during PSG) are shown in Table 2. BMI, waist 
circumference, percent body fat, and laboratory measures were 
not associated with the arousal index or the AHI. Higher BMI, 
higher waist circumference, and higher fasting and 2-h glucose 
concentrations were associated with lower nadir nocturnal 
SpO2. However, there was an outlier for nadir nocturnal SpO2 
(58%, >2 SD from the mean). When the outlier was removed, 
the association between nadir nocturnal SpO2 and BMI 
remained (r = −0.334, p =  0.012), but the associations with 
waist circumference (r = −0.0258, p = 0.055), and with fasting 
(r = −0.229, p = 0.09) and 2-h glucose (r = −0.244, p = 0.07) 
were no longer significant (Figure 1).
When only participants with NGT were evaluated, lower nadir 
SpO2 was associated with higher BMI (r = − 0.34, p = 0.04), higher 
waist circumference (r = − 0.37, p = 0.03), lower inverse fasting 
insulin (r = 0.41, p = 0.02), and IGI (r = − 0.40, p = 0.02) (Table 3). 
There were no significant relationships between laboratory and 
sleep measures in the participants with dysglycemia (Table  4). 
However, among those with T2D, nadir SpO2 was significantly 
associated with waist circumference (r = − 0.86, p = 0.007).
IFG and IGT (n =  3), FPG ≥126  mg/dL (n =  3), OGTT 2-h 
glucose ≥200  mg/dL (n =  5)]. Participants with dysglycemia 
were not significantly different from those with NGT for BMI, 
BMI SDS, or waist circumference. Percent body fat was higher 
in the group with dysglycemia (Table 1). Sleep characteristics 
among the groups divided by glycemia categories are shown in 
Table 1. There were no sex- or race-related differences in sleep 
characteristics. Seventeen (29.8%) had normal sleep studies 
with AHI <  1; 24 (42.1%) had AHI ≥1 to <5; 8 (14.0%) had 
AHI ≥5 to <10; 6 (10.5%) had AHI ≥10 to <15; 2 (3.5%) had 
AHI ≥15.
The numbers and percentages of participants meeting 
criteria for OSA based on the AHI (mild, 1 to <5 events/h; 
moderate, 5 to <10 events/h; severe, ≥10 events/h) are shown in 
Table 1. The majority of participants had an AHI <5 events/h. 
The percentage of participants meeting criteria for any degree 
of OSA was 66.7% in those with normal glycemia and 76.2% 
in those with dysglycemia. The between-group difference was 
not statistically significant (p =  0.07). Spearman’s correlation 
coefficients for the associations between laboratory markers of 
glycemia and β-cell function, and indices of sleep fragmentation 
TaBle 4 | Correlation coefficients for the associations of sleep measures with physical and metabolic parameters, dysglycemic group.
Body mass 
index
Waist 
circ.
Body fat 
(%)
hba1c Fasting 
glucose
2-h  
glucose
glucose  
areas under 
the curve
1/Fasting 
insulin
insulinogenic 
index
Oral disposition 
index
Arousal index, 
events/h
−0.038  
(0.88)
0.009  
(0.97)
−0.399  
(0.10)
0.046  
(0.86)
−0.104  
(0.68)
−0.242  
(0.35)
−0.164  
(0.53)
−0.076  
(0.77)
0.147  
(0.57)
0.201  
(0.44)
Apnea– 
hypopnea  
index, events/h
0.172  
(0.46)
0.172  
(0.46)
−0.088  
(0.70)
−0.020 
(0.93)
−0.118  
(0.61)
0.083  
(0.73)
0.170  
(0.47)
0.340  
(0.17)
−0.171  
(0.50)
0.059  
(0.82)
Nadir SpO2, % −0.225  
(0.33)
−0.331 
(0.14)
0.047  
(0.84)
−0.006 
(0.98)
0.031  
(0.89)
−0.169  
(0.48)
−0.268  
(0.25)
−0.369  
(0.13)
0.380  
(0.12)
0.157  
(0.53)
Data are Spearman’s coefficients (p values).
TaBle 3 | Correlation coefficients for the associations of sleep measures with physical and metabolic parameters, normal glucose tolerance group only.
Body mass 
index
Waist  
circ.
Body fat 
(%)
hba1c Fasting 
glucose
2-h 
glucose
glucose  
areas under  
the curve
1/Fasting 
insulin
insulinogenic 
index
Oral 
disposition  
index
Arousal index, 
events/h
−0.086  
(0.74)
−0.104  
(0.55)
0.062  
(0.74)
0.303  
(0.07)
0.034  
(0.84)
−0.037  
(0.83)
0.234  
(0.18)
0.047  
(0.79)
−0.236  
(0.19)
−0.319  
(0.07)
Apnea– 
hypopnea  
index, events/h
0.143  
(0.41)
0.247  
(0.15)
−0.064  
(0.73)
−0.029  
(0.87)
0.260  
(0.13)
0.012  
(0.95)
0.149  
(0.40)
−0.198  
(0.26)
−0.087  
(0.55)
−0.177  
(0.21)
Nadir SpO2, % −0.342  
(0.04)
−0.372  
(0.03)
0.151  
(0.40)
−0.010  
(0.95)
−0.283  
(0.10)
−0.127  
(0.46)
−0.064  
(0.72)
0.405  
(0.02)
−0.402  
(0.02)
−0.143  
(0.43)
Data are Spearman’s coefficients (p values).
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DiscUssiOn
In this pilot study, we evaluated PSG-measured sleep-disordered 
breathing in obese adolescents with a range of glucose toler-
ance. The median AHI in this study was 2.2 events/h, and the 
majority of participants had an AHI less than 5 events/h, which 
is the threshold for OSA in adults (18). Although participants 
with dysglycemia tended to have higher AHIs (median 3.2, 2.2, 
and 1.6 events/h for T2D, prediabetes, and NGT, respectively), 
there was not a linear relationship between measures of glycemia 
and AHI. The percentage of participants meeting criteria for any 
degree of OSA (AHI greater than or equal to 1 events/h) was 
66.7% in those with normal glycemia versus 76.2% in those with 
dysglycemia, although this did not meet criteria for statistical 
significance (p = 0.07). Individuals in each category of glucose 
tolerance had PSG evaluations consistent with OSA, with wide 
variability. Higher BMI, higher waist circumference, and greater 
insulin resistance (lower inverse fasting insulin) were associated 
with lower nadir SpO2 among participants with NGT. Although 
our hypothesis that youth with dysglycemia would have higher 
AHI than obese youth with NGT was not verified in this study, 
our results suggest that a study with a greater proportion of youth 
with dysglycemia and T2D is warranted and should be pursued 
through a larger network of clinical sites.
An association with nocturnal hypoxia and hyperglycemia has 
been shown in adult T2D studies, where greater levels of oxygen 
desaturation or even relatively mild intermittent hypoxemia were 
associated with poorer glycemic control (19–23). Also, improv-
ing glycemic control in adults with T2D via a pharmacological 
intervention has been associated with a decrease in nocturnal oxy-
gen desaturation (24). The mechanisms of this complex relation-
ship are not yet completely understood, but central, autonomic, 
and inflammatory mechanisms have been implicated (25–27). 
Rodent studies have shown that circulating catecholamines act 
upon α-adrenoreceptors, leading to hyperglycemia and glucose 
intolerance when intermittent hypoxia is imposed (28).
Pediatric studies have shown that OSA measured by PSG is 
associated with markers of insulin resistance as measured by fast-
ing insulin and glucose (HOMA-IR) (29, 30), OGTT (10), and 
intravenous glucose tolerance testing (31). However, pediatric 
studies examining the relationship between OSA and dysglycemia 
have had mixed results. Verhulst et al. showed the mean noctur-
nal SpO2 was independently correlated with OGTT glucose area 
under the curve in lean and obese youth aged 6–16 years (32). 
However, in the Cleveland Children’s Sleep and Health Study, 
oxygen desaturation was not associated with OGTT-stimulated 
glucose concentrations in a community-based cohort of lean and 
obese adolescents (n = 270; mean age 13.7 years; 41% with BMI 
≥85th percentile) (30). The fact that most of the participants 
were not obese in this previous study may contribute to the 
different outcomes (30). de Sousa et al. compared PSG variables 
and OGTT-derived measures of glucose tolerance in obese white 
adolescents with polycystic ovary syndrome (PCOS, n = 31) to 
those of healthy control females (n = 19) (33). This study found 
a positive correlation between AHI and HOMA-IR (r =  0.21, 
p  =  0.01), but no association between PSG parameters and 
OGTT glucose measures. The same group studied changes in 
PSG variables and OGTT glucose measures in obese adolescents 
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treated for PCOS longitudinally (n = 15, mean age 15.3 ± 1.2 y, 
28 ±  6  months between evaluations) (34). Body composition, 
PSG variables, and OGTT-derived measures of glucose metabo-
lism were unchanged from baseline. Koren et al. also found no 
association between measures of sleep-disordered breathing and 
OGTT measures (35). Similar to our study, participants were all 
obese (n =  62, mean age 14.4  years, range 8–17.5; mean BMI 
37 kg/m2) with a range of glucose tolerance. The age range was 
broader in this previous study, and the range of minimum SaO2 
values was greater in our study.
Shalitin et al. evaluated obese children and adolescents with 
and without T2D (n = 11, n = 30, respectively) with PSG and 
fasting laboratory tests (6). There were no between-group differ-
ences in AHI >5/h. The percentage of participants with AHI >5/h 
was 45% in participants with T2D, 25% in obese participants with 
IGT, and 18% in obese participants with NGT. Similarly, our study 
found: AHI >5/h was 43% in participants with dysglycemia and 
19% in obese participants without dysglycemia. In both studies, 
participants with dysglycemia were more likely to have AHI meet-
ing the criteria for OSA; however, between-group differences were 
not statistically significant in either study. Both studies lacked 
sufficient participants to adequately test the hypothesis that OSA 
occurs more frequently in obese adolescents with dysglycemia. 
It may be that obese youth are at risk for both sleep-disordered 
breathing and T2D, but the associations are weaker in youth than 
in adults. It could also be that the pathophysiology linking T2D 
and hypoxia is much more prevalent in older adults as compared 
with adolescents. A larger study in adolescents will be required to 
determine whether or not these speculations are accurate.
This study has limitations that warrant consideration. Parti-
cipants who reported snoring were recruited from obesity referral 
clinics, limiting the generalizability to the broader adolescent 
population. Participants treated with either metformin and/
or lifestyle recommendations were eligible, after discontinuing 
treatment for a short period of time. Previous treatment may have 
influenced findings in this study. The study was performed in two 
locations due to the principal investigator relocating, and PSGs 
were read and evaluated by two sleep investigators without cross-
calibrations. However, the same OGTT and PSG protocol was 
utilized in both locations. To minimize participant burden and 
enhance enrollment and participation, we opted for OGTT evalu-
ations in lieu of more invasive glucose clamp studies. Measures 
often performed in adult populations, including neck circumfer-
ence and level of crowding of oropharynx, were not performed. 
Sleep data including the percentage of time spent in REM and 
slow wave sleep and the percent of sleep time below 90% oxygen 
saturation were not uniformly available. Also, children with a his-
tory of tonsillectomy, which is a treatment for OSA in children, 
were not excluded. The data were not normally distributed, which 
was expected for glucose measures given the objective of the study. 
However, considering the preliminary nature of this investigation, 
we included all of the available data from all participants. There 
was a predominance of females in the dysglycemia group, as dys-
glycemia is more commonly occurs in female versus male adoles-
cents. As males are more likely to have sleep-disordered breathing, 
evidence of sleep-disordered breathing in obese adolescents with 
dysglycemia could be underestimated in this setting. It must be 
noted that a larger sample size is required to provide a definitive 
answer to the question of whether or not OSA is related to dys-
glycemia in adolescents. Given the nature of this pilot study, an 
adequate sample-size calculation was not performed at the onset. 
Perhaps with a larger study, including more participants with T2D, 
sleep-disordered breathing would be seen more predominantly.
Strengths of the study include a strong rationale, given the 
epidemiological prevalence of OSA in obese adults and the high 
percentage of adults with both T2D and OSA, and the lack of 
previous studies in obese adolescents. The inclusion of only obese 
pubertal patients aged 12 years and up is of particular value given 
the differences in glucose metabolism in pre-pubertal and adoles-
cent patients (7). The mean age of diagnosis of T2D in youth is 
14 years (36); thus, our cohort is representative of an appropriate 
population for evaluation of diabetes risk markers.
In conclusion, although we did not confirm the hypothesis that 
obese youth with dysglycemia have more characteristics of OSA 
than obese youth with NGT in this pilot study, we have further 
added to the literature on adolescent obesity, dysglycemia, and 
sleep characteristics. A larger study involving a network of clinical 
research sites is warranted to further understand the relationship 
between sleep-disordered breathing and dysglycemia in obese 
adolescents, especially since two pediatric studies have now shown 
a greater proportion of OSA in obese youth with dysglycemia 
versus NGT. Further study with a larger proportion of youth with 
prediabetes and T2D will also be necessary to determine whether 
evaluation for sleep-disordered breathing is uniformly warranted.
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